Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)    
$56.34 0.00 (0.00%) as of 4:30 Wed 7/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 139,010,000 as of 9/30
Market Cap: 7.83(B)
Last Volume: 1,072,880 Avg Vol: 1,248,677
52 Week Range: $56.17 - $83.28
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY       NASDAQ COMPOSITE  
    NASDAQ NNM COMPOSITE  

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   BioMarin Pharmaceutical develops and commercializes pharmaceuticals. Co.'s approved products include: Naglazyme (galsulfase) for patients with mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Aldurazyme (laronidase) for patients with mucopolysaccharidosis I; and Firdapse (amifampridine phosphate) for the treatment of Lambert Eaton Myasthenic Syndrome. Co. is also conducting clinical trials on several investigational product candidates including, among others: Vimizim™, for the treatment of mucopolysaccharidosis Type IV or Morquio Syndrome Type A; and PEG-PAL for the treatment of phenylketonuria.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 1,297
Total Buy Value $0 $0 $0 $31,835
Total People Bought 0 0 0 3
Total Buy Transactions 0 0 0 3
Total Shares Sold 19,112 82,482 267,923 1,414,787
Total Sell Value $1,121,452 $6,046,779 $18,990,759 $80,863,865
Total People Sold 5 6 9 14
Total Sell Transactions 15 20 42 155
End Date 2014-04-20 2014-01-17 2013-07-19 2012-07-19

   
Records found: 1254
  Page 1 of 51  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-07-02 4 S $64.00 $142,656 D/D (2,229) 70,905 9%     
   Grey Michael G Director   –       •      –    2014-06-06 4 A $0.00 $0 D/D 2,100 25,150     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-06-04 4 A $0.00 $0 D/D 11,400 64,426     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-06-04 4 S $62.52 $62,521 D/D (1,000) 178,257 6%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-06-04 4 A $0.00 $0 D/D 50,900 229,157     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-06-04 4 A $0.00 $0 D/D 13,800 73,134     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-06-04 4 A $0.00 $0 D/D 11,400 31,590     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-06-04 4 A $0.00 $0 D/D 12,600 99,200     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-06-04 4 A $0.00 $0 D/D 15,600 76,550     -
   Bate Kenneth Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 10,775     -
   Lawlis V Bryan Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 11,800     -
   Lapalme Pierre Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 30,150     -
   Meier Richard A Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 24,150     -
   Young William D Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 10,775     -
   Slamon Dennis Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 525 5,225     -
   Lewis Alan Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 21,400     -
   Heron Elaine J Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 19,525     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-06-03 4 D $60.00 $213,720 D/D (3,562) 53,026     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-06-03 4 S $59.88 $59,876 D/D (1,000) 179,257 4%     
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-06-02 4 AS $57.83 $21,804 D/D (377) 20,190 2%     
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-05-31 4 D $57.96 $23,937 D/D (413) 20,567     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-05-31 4 D $57.96 $17,214 D/D (297) 7,993     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-05-30 4 GD $23.21 $4,178 D/D 180 56,588     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-05-29 4 D $57.50 $218,040 D/D (3,792) 59,334     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-05-22 4 AS $56.88 $56,876 I/I (1,000) 46,195 5%     

  1254 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 51
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed